Details of the Drug | DrugMAP

General Information of Drug (ID: DMEXNZN)

Drug Name

GL-ONC1

Synonyms

olvimulogene nanivacirepvec

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
Ovarian cancer	2C73	Phase 1/2	[2]
Peritoneal carcinomatosis	2D91	Phase 1/2	[3]
Peritoneal cavity cancer	2C51.Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Oncolytic virus therapy

Cross-matching ID

TTD ID: DA6OU0

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)